Fig. 3
From: The evolution of alternative splicing in glioblastoma under therapy
a The distribution of AS event type in tumor-specific AS events, comparing primary and recurrent GBMs. b The fractions of tumor-specific AS events in cell-surface proteins, compared between primary and recurrent GBM. c The percentages of tumor-specific neojunctions found in different protein domains. d The frequencies of tumor-specific neojunctions in GBM neoplastic cells from Smart-seq2 scRNA-seq. e The fractions of cases with at least one CPTAC-confirmed neojunction. f The average number of CPTAC-confirmed neojunctions per case